The CE marking confirms that the ANA5 device complies with the European Union’s health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU.
Read more
The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and ...
Read more
Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world...
Read more
ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced the successful closing of a $65 million Series A financing round. The...
Read more
SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, announces that it has received FDA agreement for its plan to initiate a Phas...
Read more
Data support use of its ANA funnel catheter as an adjunct to stent retriever thrombectomy in the treatment of acute ischemic stroke
Read more
Anaconda Biomed, S.L., a medical technology company developing next generation neurothrombectomy devices, today announced the enrollment and treatment of the first U.S. patient in its ATHENA clinical ...
Read more
The round recognizes recent FDA alignment to advance NRTX-1001 into the Phase 3 EPIC (EPIlepsy Cell therapy) trial
Read more
Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension who would normally be treated in a specialis...
Read more
Aura Biosciences today announced positive data from a completed Phase 1 window of opportunity trial of bel-sar (AU-011) in patients with NMIBC. These data were presented by Dr. Seth Lerner as a late b...
Read more
SpliceBio today announced that it has dosed the first patient in the Phase 1/2 ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector, for the treatment of Stargardt disease. Stargardt dise...
Read more
It has been announced today the positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The research helps understand the biological basis of a rare neurodeve...
